What type of study is this?

This is a In Vitro Study study.

October 5, 2025PLoS ONEOpen Access

Revealing the molecular mechanisms underlying Xuebijing against sepsis and septic acute kidney injury via bioinformatics and experimental approaches

View Full Paper

Ask AI

Bookmark

Authors

Network pharmacology reveals Xuebijing's effects on sepsis and acute kidney injury, suggesting an anti-inflammatory mechanism.

Xuebijing significantly reduced inflammatory markers IL-1β, IL-6, and TNFα in kidney cells, indicating its therapeutic potential.
Network pharmacology identified five key targets, including MMP9 and TNF, linking Xuebijing to its effects on sepsis and septic-AKI.
Molecular docking suggested high affinity of Xuebijing's components for MMP9 and TNFα, underscoring its anti-inflammatory action.
In vitro experiments confirmed Xuebijing's ability to suppress inflammatory signaling pathways associated with acute kidney injury.

Li et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

October 5, 2025PLoS ONEOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Network pharmacology reveals Xuebijing's effects on sepsis and acute kidney injury, suggesting an anti-inflammatory mechanism.

Xuebijing significantly reduced inflammatory markers IL-1β, IL-6, and TNFα in kidney cells, indicating its therapeutic potential.
Network pharmacology identified five key targets, including MMP9 and TNF, linking Xuebijing to its effects on sepsis and septic-AKI.
Molecular docking suggested high affinity of Xuebijing's components for MMP9 and TNFα, underscoring its anti-inflammatory action.
In vitro experiments confirmed Xuebijing's ability to suppress inflammatory signaling pathways associated with acute kidney injury.

Li et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark